Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
117 studies found for:    "Intraocular melanoma"
Show Display Options
Rank Status Study
1 Recruiting Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
2 Completed Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Genetic: fluorescence in situ hybridization;   Other: laboratory biomarker analysis;   Procedure: fine-needle aspiration;   Procedure: therapeutic conventional surgery;   Other: Questionnaires
3 Unknown  Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
Condition: Intraocular Melanoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies
4 Completed
Has Results
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
Condition: Intraocular Melanoma
Intervention: Drug: nab-paclitaxel
5 Completed New Biopsy Technique for Uveal Melanoma
Condition: Uveal Melanoma
Intervention:
6 Active, not recruiting Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Drug: AEB071
7 Recruiting Intermittent Selumetinib for Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: Selumetinib
8 Recruiting Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: Adjuvant chemotherapy by Fotemustin;   Other: Intensive surveillance
9 Recruiting Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Condition: Uveal Melanoma
Interventions: Procedure: SIRT;   Procedure: DSM-TACE
10 Recruiting A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Condition: Uveal Melanoma
Intervention: Drug: LXS196
11 Recruiting Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma
Condition: Uveal Melanoma, Monosomy 3 Positive, no Evidence for Metastases.
Intervention: Biological: Autologous Dendritic Cells loaded with autologous Tumor RNA
12 Terminated Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Condition: Uveal Melanoma
Intervention: Biological: autologous dendritic cells electroporated with mRNA
13 Completed
Has Results
Treatment With Intravitreal Avastin for Large Uveal Melanomas
Condition: Uveal Melanoma
Intervention: Drug: AVASTIN
14 Recruiting Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Condition: Uveal Melanoma
Intervention: Drug: Crizotinib
15 Active, not recruiting Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: CP-675,206
16 Active, not recruiting Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Procedure: Intraoperative ultrasonography
17 Recruiting Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Radiation: Hypofractionated linear accelerator radiotherapy
18 Completed RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
19 Active, not recruiting A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: Placebo;   Drug: Sorafenib
20 Terminated
Has Results
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: AEB071;   Drug: MEK162

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.